Pharmacy Innovations: Drug Recall

Recall #D-0234-2023 · 12/22/2022

Class II: Risk

Recall Details

Recall Number: D-0234-2023
Classification: Class II
Product Type: Drug
Recalling Firm: Pharmacy Innovations
Status: Terminated
Date Initiated: 12/22/2022
Location: Erie, PA, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: N/A

Reason for Recall

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Product Description

PROSTAGLANDIN (PE1) 45MCG (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 17MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 20MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 22.5MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 23MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 30MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 40MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 44.5MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 45MCG/ML (3ML VIAL) INJECTABLE PROSTAGLANDIN E1 50MCG/ML (1ML VIAL) INJECTION PROSTAGLANDIN E1 60MCG/ML (1ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.

Distribution Pattern

Nationwide in the USA

Other Recalls by Pharmacy Innovations

Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

View all recalls by Pharmacy Innovations →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.